Welcome to our dedicated page for Biomarin Pharmaceutical news (Ticker: BMRN), a resource for investors and traders seeking the latest updates and insights on Biomarin Pharmaceutical stock.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a global rare disease biotechnology company focused on medicines for genetically defined conditions. This news page aggregates company announcements, press releases and event updates so readers can follow how BioMarin’s strategy, pipeline and commercial portfolio evolve over time.
Recent communications from BioMarin highlight its emphasis on Enzyme Therapies and Skeletal Conditions business units, as well as its work with ROCTAVIAN, a gene therapy for hemophilia A. The company issues news on topics such as financial results, long-term guidance, corporate strategy, business development transactions, clinical data presentations and regulatory milestones for its therapies.
Examples of news themes include updates on VOXZOGO in achondroplasia and other skeletal conditions, progress with PALYNZIQ in phenylketonuria, development of BMN 401 for ENPP1 deficiency and other pipeline programs in rare genetic diseases. BioMarin also reports on strategic partnerships, such as digital and data collaborations, and on planned acquisitions intended to expand and diversify its rare disease portfolio.
Investors and followers of BMRN can use this page to review earnings announcements, conference presentations, investor day materials and product-specific updates released through newswires. By checking this feed regularly, readers can see how BioMarin describes its growth priorities, clinical milestones and capital allocation decisions across its rare disease franchises.
BioMarin (Nasdaq: BMRN) reported new data showing early treatment with VOXZOGO (vosoritide) improves proportionality, arm span and BMI in children with achondroplasia, with durable multi-year gains. Key findings include a 4.7 cm additional height gain after four years and ULBR improvement to −0.53 by year four. Real-world data cover >5,000 infants and children across 50+ countries and align with clinical-trial results supporting earlier treatment.
BioMarin (Nasdaq: BMRN) announced FDA approval of PALYNZIQ (pegvaliase-pqpz) for adolescents aged 12 and older with phenylketonuria (PKU).
Approval is based on Phase 3 PEGASUS data: mean blood Phe fell from 1025 to 567 µmol/L at Week 72 on PALYNZIQ versus 1029 to 973 µmol/L on diet alone, with a treatment difference of -409 µmol/L (95% CI -579, -240). Common adverse reactions (≥20%) included injection site reactions, arthralgia, headache and hypersensitivity reactions.
BioMarin (NASDAQ: BMRN) announced management will participate in four investor conferences in March 2026: TD Cowen (Mar 4), Leerink (Mar 9), Jefferies Biotech on the Bay (Mar 10) and Barclays Global Healthcare (Mar 11).
Executives will take part in fireside chats, 1x1 meetings, and live webcasts; replay will be available for a limited time.
BioMarin (NASDAQ: BMRN) reported full-year 2025 total revenues of $3.22B, up 13% year-over-year, and fourth-quarter revenues of $875M, up 17% YoY. VOXZOGO revenue rose 26% in 2025 to $927M; Enzyme Therapies grew 9% to $2.105B.
The company announced a definitive agreement to acquire Amicus, expects close in Q2'26, and provided 2026 guidance excluding Amicus: total revenues $3.325–3.425B and Non-GAAP diluted EPS $4.95–5.15. BioMarin voluntarily withdrew ROCTAVIAN, taking ~ $240M charges in Q4'25.
Phenylketonuria market (includes BioMarin - BMRN) is forecast to expand through 2034 driven by rising diagnosis rates, expanded newborn screening, and multiple emerging therapies.
Key datapoints: US had 18,800 diagnosed PKU cases in 2024; sepiapterin received regulatory approvals in 2025 and pegvaliase sBLA entered FDA review.
BioMarin (NASDAQ: BMRN) will host a conference call and webcast on Monday, February 23, 2026 at 4:30 p.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a business update.
Alexander Hardy, President and CEO, will lead the call. Dial-in numbers, replay details, and a live webcast are available via the company's investor website; a replay will be archived for one week.
BioMarin (NASDAQ: BMRN) closed a private offering of $850 million 5.500% senior unsecured notes due 2034 at 100% issue price to help fund its pending acquisition of Amicus.
The company plans to combine the Notes, a $2.0 billion Term Loan B, a $800 million Term Loan A, a proposed $600 million revolver and cash to pay acquisition consideration, fees and related borrowings.
Proceeds were placed in escrow; mandatory redemption triggers apply if the acquisition is not completed by December 19, 2026.
BioMarin (NASDAQ: BMRN) priced an $850 million offering of 5.500% senior unsecured notes due 2034 at 100% with expected close on February 12, 2026, and completed syndication of a $2.0 billion Term Loan B facility.
The company also has a $800 million Term Loan A and expects a $600 million revolver; proceeds and borrowings will fund the pending acquisition of Amicus and related fees. Notes proceeds will be held in escrow and must be redeemed if the acquisition is not completed by December 19, 2026.
BioMarin (NASDAQ: BMRN) announced a proposed private offering of $850 million senior unsecured notes due 2034 and launched syndication for a new $2.0 billion senior secured Term Loan B facility, in addition to an $800 million Term Loan A facility and a $600 million senior secured revolving facility to support its pending acquisition of Amicus.
Net proceeds from the notes, borrowings under the new senior secured credit facilities and cash on hand are intended to fund acquisition consideration, fees and expenses. Gross note proceeds will be placed in escrow and must be redeemed if the acquisition is not completed on or prior to December 19, 2026 (subject to specified events). The notes will be guaranteed by certain subsidiaries and will include customary covenants and transfer restrictions.
Freddie Mac (OTCQB: FMCC) reported 2025 multifamily production of $77.6 billion, a 17% increase versus 2024, supporting over 577,000 affordable rental units nationwide. The total includes $1.2 billion in LIHTC equity, $1.1 billion in workforce housing preservation loans, and $2.4 billion in forward conversions.
Freddie Mac said it set records in forward commitments and long-term financing, with $2.0 billion in new long-term funding (+42%) and Structured Products totaling $2.5 billion (including $2.2 billion of Q-Deals). The company reported 66% of 2025 volume met its mission-driven affordable housing goal, exceeding the 50% target.